| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg | |||
| Other Sizes |
| Targets |
(R)-INCB054329 does not have specific pharmacological targets, as it is the inactive isomer of the BET inhibitor INCB054329. The compound is used as a control in experiments to distinguish the specific effects of BET inhibition from non-specific effects. As an inactive isomer, it is not expected to significantly inhibit BET bromodomains.
|
|---|---|
| ln Vitro |
(R)-INCB054329 is not evaluated for traditional biological activity, as it is an inactive isomer used as a control compound. The active isomer, INCB054329, is a potent BET inhibitor. (R)-INCB054329 is used to control for non-specific effects in experiments evaluating BET inhibition. No specific in vitro activity data have been reported for this compound.
|
| ln Vivo |
(R)-INCB054329 is not used for in vivo pharmacological evaluation as an active compound. It is the inactive isomer of INCB054329 and is used as a control in experiments. The compound may be used in animal studies as a negative control to distinguish the effects of BET inhibition from non-specific effects.
|
| Enzyme Assay |
(R)-INCB054329 is not evaluated in traditional enzyme/receptor binding assays as an active compound. It serves as a control in experiments where the active isomer INCB054329 is being studied. In such experiments, both the active and inactive isomers are tested in parallel under identical assay conditions to control for non-specific effects. The compound's purity is confirmed by HPLC. Purity ≥98%.
|
| Cell Assay |
(R)-INCB054329 is not evaluated in traditional cellular assays as an active compound. It is used as a control in experiments where the active isomer INCB054329 is being studied. Cells are treated with both the active and inactive isomers, and effects on cell viability, proliferation, or signaling pathways are compared to establish the specificity of BET inhibition.
|
| Animal Protocol |
(R)-INCB054329 is not used in in vivo animal experiments as an active compound. It is the inactive isomer of INCB054329 and may be used as a control in animal studies. The compound helps distinguish the specific effects of BET inhibition from non-specific effects in vivo.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of (R)-INCB054329 have not been extensively characterized. The compound has a molecular weight of 348.36 g/mol and a molecular formula of C₁₉H₁₆N₄O₃. As a small molecule with heterocyclic aromatic moieties, it is expected to have reasonable membrane permeability. The compound is the inactive isomer of INCB054329.
|
| Toxicity/Toxicokinetics |
The toxicological profile of (R)-INCB054329 has not been extensively documented, as it is an inactive isomer used as a control compound. Standard laboratory safety precautions should be followed when handling this compound. The compound is not intended for therapeutic use.
|
| References | |
| Additional Infomation |
(R)-INCB054329 (CAS# 1628607-63-5, molecular formula C₁₉H₁₆N₄O₃, molecular weight 348.36) is the inactive isomer of the potent BET inhibitor INCB054329. Used as an experimental control. No clinical trials or regulatory approvals have been identified. Purity ≥98%.
|
| Molecular Formula |
C19H16N4O3
|
|---|---|
| Molecular Weight |
348.355343818665
|
| Exact Mass |
348.122
|
| CAS # |
1628607-63-5
|
| Related CAS # |
INCB054329;1628607-64-6;INCB054329 Racemate;1628607-62-4
|
| PubChem CID |
90410077
|
| Appearance |
Light yellow to yellow solid powder
|
| LogP |
1.9
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
26
|
| Complexity |
561
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C2=C(C3=C(C)ON=C3C)C=CC3NC(=O)N(C2=3)[C@H](C2=NC=CC=C2)C1
|
| InChi Key |
XYLPKCDRAAYATL-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C19H16N4O3/c1-10-16(11(2)26-22-10)12-6-7-14-17-18(12)25-9-15(23(17)19(24)21-14)13-5-3-4-8-20-13/h3-8,15H,9H2,1-2H3,(H,21,24)/t15-/m0/s1
|
| Chemical Name |
(11R)-7-(3,5-dimethyl-1,2-oxazol-4-yl)-11-pyridin-2-yl-9-oxa-1,3-diazatricyclo[6.3.1.04,12]dodeca-4(12),5,7-trien-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (287.06 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8706 mL | 14.3530 mL | 28.7059 mL | |
| 5 mM | 0.5741 mL | 2.8706 mL | 5.7412 mL | |
| 10 mM | 0.2871 mL | 1.4353 mL | 2.8706 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
